Top London Biotech Companies (133)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.
LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess. The company is working with a range of pharmaceutical license partners to develop a portfolio of CAR-IMAN cell therapies to deliver complete remission across all solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer. See www.liftbiosciences.com. We are now speaking to syndicate partners for our forthcoming Series A POC Clinical Trial, and co-development partners for commercialisation
Eternal is solving the absence of a properly sustainable and cost-effective protein ingredient that is flavor neutral. The company uses AI and computer vision to improve the fungi fermentation techniques of existing and approved strains. The result is a market-ready product that suits better the needs of a range of food manufacturers, reducing the amount of post processing needed for an end product
Genz is a spin-off biotech company developing novel solutions from in vitro diagnostics to therapeutics. Our mission is to deliver a consistent stream of innovative, affordable, and accessible diagnostic solutions and make a remarkable impact on people’s lives. We’re focused on sustainable growth and addressing the world’s pressing health challenges; therefore, we’re able to create value for both our patients and our shareholders. To date, Genz developed 4 IVD diagnostic tests commercially legalized, attended International joint projects, partnered with top research centers in the world and published several scientific articles in international scientific journal
CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific therapeutics to the gut. CHAIN’s Clostridium Assisted Drug Delivery (CADD™) delivery platform is highly differentiated and supports a therapeutic product pipeline for a wide range of clinical indications including localised infection, inflammation and CNS signalling. Our lead asset is an engineered strain that secretes a novel and potent anti-inflammatory molecule targeting Inflammatory Bowel Disease, a chronic gut disease affecting millions worldwide.
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.
Apian is transforming healthcare logistics, bringing everyday on-demand delivery to the NHS and beyond. Faster deliveries to more patients with less emissions
We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
Synthace is a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. It allows biologists to design, plan, and automate experiments in a single place, then automatically gather structured experiment data and metadata in a unified no-code environment.
Mapping the immune system in unprecedented detail and scale. IMU’s discovery platform is building a new understanding of the immune system across health and disease, through next generation high resolution, systems-level immune profiling with AI and machine learning analytics
biomodal is an omics based life-sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solution enables more epigenetic information from a single, low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Our single-base-resolution, phased sequencing approach unlocks the combinatorial power of genetic and epigenetic information in one workflow, elucidating greater biological insight within the fields of cancer, neurodegenerative disease, and ageing.
MultiplAI Health is a preventive medicine company pioneering blood screening for cardiovascular and other complex diseases. Powered by genomic RNAseq, proprietary data transformation, and comprehensive AI analysis, our test transforms a single blood sample into a precision, actionable risk assessment to drive proactive health management that will extend lifespan. We have a laboratory-validated prototype and are conducting our sixth clinical study to achieve technical validation of our whole-blood liquid biopsy approach in the cardiovascular space
Phastar is a specialist biometrics contract research organization offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships. Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 4,000 years accumulated technical experience across the company. Phastar is headquartered in London (UK) and North Carolina (US) and has 15 offices worldwide
The future of fertility care is here. Béa Treatment – fertility treatment delivered straight to your door. Join the UK's largest home fertility study
At Epoch, we use advanced biodesign to develop natural solutions to unnatural problems. We have started by designing and scaling the first enzymes capable of transforming plastics into low-carbon, circular chemicals.
Founded in 2013, Eleusis is a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design. The company’s comprehensive discovery and development capabilities, together with Andala’s care delivery platform, enable it to target a broad spectrum of unmet needs within psychiatry and beyond psychiatry.
Ascend is a development partner that supports life-science innovators in bringing gene therapy products to patients. Our team of experts have more than 120 years of combined experience in gene therapy development and commercialization to offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested in a world-class analytical toolkit within our flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. Let’s aim higher and develop the next wave of accessible life-saving therapies together
Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.
Work Your Passion. Live Your Purpose.
